UK Regulatory Consulting Services — MHRA Compliance & Regulatory Affairs
Specialist regulatory affairs consulting services for United Kingdom — covering MHRA requirements and all major regulatory frameworks.
UK regulatory consulting services are in high demand in the post-Brexit regulatory environment. Since the UK’s exit from the EU, MHRA has operated as an independent regulatory authority with its own submission requirements, compliance standards, and product approval processes — separate from EMA and EU MDR. For companies seeking UK market access, dedicated UK regulatory affairs consulting is essential to navigate MHRA’s evolving requirements effectively.
Regulations & Requirements — United Kingdom
- MHRA guidance documents (post-Brexit)
- UK MDR 2002 (as amended for UKCA)
- Human Medicines Regulations 2012
- UK GMP Orange Guide requirements
- MHRA Good Pharmacovigilance Practice (GVP)
Our United Kingdom Regulatory Consulting Services
MHRA regulatory consulting services
UK MAA preparation and MHRA submission
UK medical device regulatory services
UKCA registration and MHRA registration
MHRA compliance consulting
GMP, pharmacovigilance, post-market obligations
UK regulatory submission services
rolling review, MHRA scientific advice
Life sciences regulatory consulting UK
strategy for GB and NI market access
UK regulatory strategy consulting
post-Brexit regulatory planning
Pharmaceutical regulatory consulting UK
UK MAA, line extensions, variations
Regulatory Consulting Services in United Kingdom
RABT Global provides specialist regulatory consulting services in United Kingdom — covering pharmaceutical drug registration, medical device regulatory compliance, clinical trial applications, and ongoing regulatory lifecycle management under MHRA regulatory requirements. Our United Kingdom regulatory consulting team combines in-country regulatory experience with global life sciences expertise to deliver effective, efficient regulatory programmes for every client.
United Kingdom Regulatory Consulting — FAQs
A: Since 1 January 2021, the UK (Great Britain) has operated under MHRA’s independent regulatory framework. EU marketing authorisations are no longer valid in GB — separate UK MAAs are required. For medical devices, CE marks are accepted until 30 June 2025, after which UKCA marking will be required for most device classes. RABT Global’s UK regulatory consulting services provide expert guidance on all post-Brexit regulatory obligations.
A: Yes. Products marketed in Great Britain (England, Scotland, Wales) require a UK marketing authorisation from MHRA. Products in Northern Ireland may continue to benefit from EU mutual recognition arrangements under the Windsor Framework. RABT Global’s MHRA regulatory consulting services manage the full UK MAA process for pharmaceutical and medical device companies.
A: RABT Global brings specialist MHRA regulatory expertise combined with a global regulatory perspective. Our United Kingdom regulatory consulting services are delivered by dedicated in-country regulatory specialists — ensuring accurate, up-to-date guidance on all aspects of United Kingdom regulatory requirements for pharmaceutical and medical device companies.
Navigate United Kingdom Regulatory Requirements with Confidence
Expert regulatory consulting services for United Kingdom. MHRA compliance. Market access. Delivered by RABT Global’s specialist United Kingdom regulatory team.